Astellas Pharma Reported Earnings

Astellas Pharma (ALPMY) reported earnings of $0.60 per share on revenue of $4.02 billion for the fiscal first quarter ended June 2026. . Revenue grew 14.87% on a year-over-year basis.

Astellas Pharma Inc and its subsidiaries are engaged in manufacturing, marketing and import/export of pharmaceuticals. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs.